AstraZeneca PLC
As of Oct 23, 2026 close
- Market cap
- $267.52B
- P/E (TTM)
- 25.61
- Forward P/E
- 20.59
- Dividend yield
- 1.87%
- 52-week range
- $81.02$212.71
- Volume (live)
- -
- Avg. volume (3M)
- 2.79M
AstraZeneca (AZN) Stock Price & Financial Analysis
AstraZeneca Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $169.51 - $171.75 |
|---|---|
| 52-Week High | $212.71 |
| 52-Week Low | $81.02 |
| Open | $171.28 |
| Volume (last close) | 3.69M |
| Average Volume (3M) | 2.79M |
| Revenue (TTM) | 61.37B |
|---|---|
| Net Income (TTM) | 10.45B |
| Free Cash Flow (TTM) | 8.39B |
| EPS (TTM) | $6.69 |
| Profit Margin | 17.02% |
| Operating Margin | 22.77% |
| Return on Equity (ROE) | 20.77% |
| Debt to Equity | 0.59 |
| Annual Dividend | $3.23 |
|---|---|
| Dividend Yield | 1.87% |
| Payout Ratio | 48.28% |
| Last Dividend Ex-Date | Aug 7, 2026 |
| Market Cap | 267.52B |
|---|---|
| Shares Outstanding | 1.56B |
| P/E Ratio (TTM) | 25.61 |
| Forward P/E | 20.59 |
| Price to Sales (P/S) | 4.36 |
| Price to Book (P/B) | 5.32 |
| EV/EBITDA | 14.58 |
| 50-Day MA | $162.32 |
|---|---|
| 200-Day MA | $180.64 |
| 1-Year Change | +106.92% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
AstraZeneca at a Glance
As of the Oct 23, 2026 close, AstraZeneca (AZN) has a market capitalization of $267.52B. The stock trades at 25.6× trailing earnings, 20.6× forward earnings and 4.4× sales. Over the trailing twelve months it earned $10.45B on revenue of $61.37B (a 17.0% profit margin) and generated $8.39B of free cash flow. Revenue grew 8.6% year over year.
As of its latest reported balance sheet, it holds $4.89B in cash and securities against $29.49B of debt, a net debt position of $24.60B.
AstraZeneca pays a semi-annual dividend totaling $3.23 per share a year, a 1.87% yield at the Oct 23, 2026 close, with a 48% payout ratio and 2 consecutive years of dividend increases.
The share price is up 106.9% over the past year. At $171.49 (the Oct 23, 2026 close) it sits within its 52-week range of $81.02 to $212.71, below its 200-day moving average of $180.64.
Based on 18 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $211.46, 23.3% above the Oct 23, 2026 close.
Frequently Asked Questions About AstraZeneca
What is the current stock price for AZN?
As of the Oct 23, 2026 close, AZN stock trades at $171.49. The 52-week range is $81.02–$212.71, with a day range of $169.51–$171.75.
What is the P/E ratio for AZN?
As of the Oct 23, 2026 close, AstraZeneca's trailing twelve-month (TTM) P/E ratio is 25.6, meaning investors pay $25.6 for every $1 of annual earnings. The forward P/E is 20.6, reflecting analyst expectations for future earnings. AstraZeneca operates in the Healthcare sector.
Does AZN pay dividends?
Yes, AstraZeneca pays a 1.87% annual dividend yield as of the Oct 23, 2026 close ($3.23 per share a year). The trailing twelve-month payout ratio is 48.3%. The most recent ex-dividend date was August 7, 2026.
What do analysts recommend for AZN?
Based on ratings from 18 professional analysts over the last 90 days, the consensus for AZN is Buy. The average 12-month price target is $211.46, a 23.3% upside from the Oct 23, 2026 close of $171.49.
What is the market cap of AZN?
As of the Oct 23, 2026 close, AstraZeneca's market capitalization is $267.52B, classifying it as a mega-cap company. AstraZeneca operates in the Healthcare sector within the Drug Manufacturers - General industry.